[Cardiotoxicity in long term treatment with cytostatics (author's transl)].
During cytostatic combination treatment with five different anti-tumor agents two female patients suffered from cardiac failure which proved fatal. This was mainly due to doxorubicine (adriamycin) and daunorubicine. In an 8-year-old patient the cumulative dose was reached after 14 months of treatment (total dose of adriamycin 420 mg/m2, of daunorubicine 280 mg/m2) and in a 7-year-old patient after 16 months (total dose of adriamycin 480 mg/m2, of daunorubicine 280 mg/m2). Cardiac failure which occurred 12 months after the onset of treatment in a 12-year-old girl (total dose of adriamycin 310 mg/m2 and of daunorubicine 280 mg/m2) could be brought under control. The cumulative dose of adriamycin should be limited to 500 mg/m2 in children without risk factors.
D001859:Bone Neoplasms / Q000188:drug therapy; D002648:Child; D003630:Daunorubicin / Q000009:adverse effects*; D004317:Doxorubicin / Q000009:adverse effects*; D005153:Facial Neoplasms / Q000188:drug therapy; D005260:Female; D006333:Heart Failure / Q000139:chemically induced*; D006801:Humans; D006811:Humerus; D012516:Osteosarcoma / Q000188:drug therapy; D012208:Rhabdomyosarcoma / Q000188:drug therapy; D012447:Sacrum; D012512:Sarcoma, Ewing / Q000188:drug therapy; D013997:Time Factors
D004317:Doxorubicin; D003630:Daunorubicin
Kardiotoxizität bei Langzeittherapie mit Zytostatika.